doi: 10.1089/can.2019.0036.eCollection 2020.
- PMID: 32923662
- PMCID: PMC7480712
- DOI: 10.1089/can.2019.0036
Abstract
Introduction: Previous studies have shown that cannabis use is common in adults with sickle cell disease (SCD), and that many patients report using cannabis to treat pain.
Methods: We performed a cross-sectional study of adults with SCD and compared daily users of cannabis with others using validated patient-reported measures of pain and quality of life as well as opioid and health care utilization.
Results: Daily cannabis users with SCD had worse pain episode severity scores than others (56.7 vs. 48.8, p=0.02) yet had 1.8 fewer annual admissions (p=0.01) and 1.2 fewer annual emergency room (ER) visits (p=0.01), and similar amounts of opioids dispensed to others after matching for age, gender, SCD genotype, hydroxyurea use, and pain impact scores.
Conclusions: We show that people with SCD with more severe pain crisis are more likely to use daily cannabis, yet have lower rates of hospital admission and ER use as compared with others with similar disease severity and pain impact. Randomized controlled trials should be performed.
Keywords: cannabinoid, cannabis, pain, sickle cell disease
Copyright 2020, Mary Ann Liebert, Inc., publishers.
Conflict of interest statement
M.D. is employed by Regeneron Pharmaceuticals. This relationship was not related to the development of this article. All other authors report no relevant disclosures/competing interests.
